Starting your first faculty position can be both exciting and overwhelming. In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Arthi Sridhar to discuss the transition from fellowship to independent practice, sharing practical insights on navigating clinical responsibilities, building professional relationships, balancing personal and professional priorities, and developing a sustainable career in oncology. Whether you're beginning a career in academic or community practice, this conversation offers actionable advice to help you thrive in your early years as faculty. Guests: Arthi Sridhar, MD - [email protected] Assistant Professor, Department of Internal Medicine Harold C. Simmons Comprehensive Cancer Center UT Southwestern Medical Center

In this episode of Lung Cancer Considered, Dr. Balazs Halmos reflects on a career at the forefront of thoracic oncology, sharing the pivotal moments, lessons learned, and hard truths that have shaped modern lung cancer care. Guest: Balazs Halmos, MD, MS Professor of Medicine Associate Director, Clinical Science Montefiore Einstein Comprehensive Cancer Center

This episode of Lung Cancer Considered provide a preview of the upcoming IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea this September. Key topics covered include WCLC26 highlights - Multidisciplinary, WCLC26 deadlines and information about Seoul. Guests: Myung-Ju Ahn, MD, PhD Distinguished Professor Section of Hematology-Oncology, Department of Medicine Hanyang University Medical Center, Hanyang University School of Medicine Seoul, Republic of Korea Vincent Wentao Fang, MD Professor, Department of Thoracic Surgery Shanghai East Hospital Tongji University Medical School Jiraporn Setakornnukul, MD, PhD Radiation Oncologist, Associate Professor Division of Radiation Oncology Department of Radiology Faculty of Medicine, Siriraj Hospital Mahidol University Bangkok, Thailand Yasushi Yatabe, MD, PhD Chief, Department of Diagnostic Pathology, National Cancer Center Hospital Chief, Division of Molecular Pathology, National Cancer Center Research Institute National Cancer Center Japan

In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape. Guests: Julie R. Brahmer, MD, MSc, FASCO, FAIO The Marilyn Meyerhoff Professor of Thoracic Oncology Co-Leader, Cancer Immunology Research Program Co-Director, Upper Aerodigestive Cancers Program Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus Professor Solange Peters, MD, PhD Chair of Medical Oncology Director of Oncology Department - CHUV Lausanne University Hospital

In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages. Guests: Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care. Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO

In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Natalie Brown and Dr. Aurora Lucas to explore how patients and caregivers are using artificial intelligence in the context of lung cancer care. The discussion highlights real-world experiences, addressing both the benefits of AI in improving understanding and empowerment, and the risks of misinformation, overreliance, and lack of personalization. The conversation also offers practical guidance for patients, families, and clinicians on using AI responsibly while reinforcing the importance of partnership with the care team. Guests: Aurora Lucas, EdD Lung Cancer Patient Advocate Natalie S. Brown, MBA Lung Cancer Advocate & Speaker Founder, Beyond The Diagnosis LLC

As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Andrea Fillipi and Dr. Piergiorgio Solli. The tumor board focuses on the management of resectable EGFR-mutant NSCLC. Host: • Alfredo Addeo, MD Head of Oncology Service University Hospital Geneva Guests: Andrea R. Filippi, MD Head of Radiation Oncology, Fondazione Istituto Nazionale dei Tumori, Milan Associate Professor, Radiation Therapy Department of Oncology, University of Milan Piergiorgio Solli, MD, PhD Head of Thoracic Surgery IRCCS Fondazione Istituto Nazionale dei Tumori, Milan

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS updates from the American Association for Cancer Research (AACR) 2026 Annual Meeting with Dr. Deborah Doroshow, Dr. David S. Hong, and Dr. Jonathan Riess. Guests: Deborah Doroshow, MD, PhD Associate Professor of Medicine, Hematology/Oncology Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai David S. Hong, MD Douglas E. Johnson Endowed Professor Deputy Chair, Department of Investigational Cancer Therapeutics [A Phase I Program] Division of Cancer Medicine Clinical Medical Director, Clinical and Translational Research Center The University of Texas MD Anderson Cancer Center Jonathan Riess, MD Associate Professor of Medicine, UC Davis Comprehensive Cancer Center Director of Thoracic Oncology, University of California, Davis

This episode of Lung Cancer Considered, part of IASLC’s World Language Series, features host Dr. Narjust Florez leading a Spanish-language discussion with Dr. José Corona-Cruz and Dr. Diego Carrillo on perioperative chemoimmunotherapy in early-stage lung cancer. Using a real-world case, they explore clinical decision-making, biomarker considerations, and surgical challenges, with a focus on implementation barriers in Latin America. The conversation highlights multidisciplinary strategies and practical insights to optimize care in resource-variable settings.

This episode of LCC covers the work of our nursing and allied health professional committee and, most importantly, highlight their role in the care of patients with thoracic malignancies. Guests: Professor Nicole Kiss is a Fellow of Dietitians Australia and Clinical Associate Professor in the Institute for Physical Activity and Nutrition at Deakin University. Nicole co-leads the Exercise and Nutrition for Cancer research group, with her research focused on early identification of cancer-related muscle loss and improving access to treatment. Dr. Morten Quist is a former IASLC Board member and is currently an Associate Professor and Research Physiotherapist at the University Hospital of Copenhagen, Rigshospitalet. For the past 25 years, he has pioneered clinical exercise-based rehabilitation for people living with cancer, with a primary focus on exercise, prehabilitation, and rehabilitation in lung cancer. His work bridges research, clinical care, patient advocacy, and voluntary engagement – always with patient wellbeing at the center.